Candel Therapeutics, Inc. (CADL) News
Filter CADL News Items
CADL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CADL News Highlights
- CADL's 30 day story count now stands at 2.
- Over the past 1 day, the trend for CADL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CADL are DEC, DRUG and PD.
Latest CADL News From Around the Web
Below are the latest news stories about CANDEL THERAPEUTICS INC that investors may wish to consider to help them evaluate CADL as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning! |
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer. |
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic CancerNEEDHAM, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PD |
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and prostate cancer in 2024Prioritizes development of CAN-3110 in recurrent high-grade glioma and initiation of investigational new drug (IND)-enabling studies in second indicationPlans to broaden discovery partnership opportunities based on the enLIGHTEN™ Discovery PlatformExtends cash run |
Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical ProgressAdvancements in Viral Immunotherapy Trials and Financial Health |
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsInitial survival data from phase 2 clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) showed survival supportive of an increased tail on the maturing survival curveInitial data from phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer demonstrated an estimated survival rate of 71.4% at 36 months in patients treated with both CAN-2409 and standard of care (SoC) chemoradiation versus 16.7% in the control arm after standard of care (SoC) chemoradiatio |
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITCThe first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillanceApplication of the enLIGHTEN™ Advanced Analytics suite to datasets from immune checkpoint inhibitor (ICI)-treated patients enabled in silico prediction and subsequent preclinical validation of multi-gene payload combinations to overcome lack of response to ICICandel’s enLIGHTEN™ Discovery Platform is the first systematic, i |
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerInitial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409 Estimated overall survival rate was 71.4% at 36 months in CAN-2409 treated patients versus 16.7% in the control arm after chemoradiation In patients with progressive disease, there was both a CA19-9 and a survival response to salvage chemotherapy in the CAN-2409 arm, but not in the control arm.Dense aggregates of im |
Pleasing Signs As A Number Of Insiders Buy Candel Therapeutics StockUsually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like... |
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110CAN-3110 is a first-in-class herpes simplex virus-1 oncolytic immunotherapy candidate with dual activity for oncolysis and immune activation in a single therapeuticIn a first-in-human clinical trial of CAN-3110 in recurrent high-grade glioma, CAN-3110 was well tolerated and treatment was associate with improved survivalPositive HSV-1 serology, before or after CAN-3110 injection, was a predictor of response and was associated with improved survivalIncreased infiltrating immune cells in the tumor |